HUTCHMED hosts expert webcast on savolitinib Phase III data in lung cancer
HCM•HUTCHMED will co-host an investor and analyst webcast with Citigroup on November 5, 2026, to discuss Phase III savolitinib data in MET-driven non-small cell lung cancer and the global regulatory outlook.
1. Webcast details
The webcast will begin at 4:30 p.m. HKT (8:30 a.m. GMT / 3:30 a.m. EST) and cover development progress as well as the global regulatory outlook for savolitinib.
